Biosimilars - advantages and prospects

Biotechnologie is a rapidly developing branch of modern science, which is increasingly used in various fields, especially in medicine. Increasingly developed and introduced into medical practice of new Biopharmaceuticals - medicines derived from modern biotechnology. The development of technology in the production of “similar” medicines is gaining momentum and leads to a reduction in the cost and availability of drugs. On biotech drugs now pinning major hopes on a more affordable means of combating the most dangerous non-communicable diseases of modernity, such as cancer, multiple sclerosis, Alzheimer’s disease, storage diseases, etc. In this review we will discuss what is the difference between the original medicinal substance from the generic, and what is the bioequivalent. To date, the biosimilars market is actively developing and has very good growth prospects. According to experts of the pharmaceutical industry in the coming years, the biologics will be at least 50% of all medicines.

biosimilars, generic drugs, biotechnology, pharmaceuticals, biotech drugs, биоаналоги, дженерики, биотехнология, лекарственные средства, биотехнологические препараты

1. The Commission of the European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official J Eur Union 2004; 47(L159): 46-94.

2. Misra A. Are biosimilars really generics? Expert Opin. Biol. Ther. 2010; 10(4): 489-4, Goldsmith D., Kuhlmann M., Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol. 2007;11: 1915.

3. Дугин И. На мировом фармрынке доминируют препараты. ФВ. Фармвестник. Available from: http://www.pharmvestnik.ru/publs/lenta/obzory/na-mirovom-farmrynke-dominirujut-biopreparaty.html#.U0wwBFV_tc0 (дата обращения 15.01.2015)

4. Сазыкин Ю.О., Орехов С.Н., Чакалева И.И. Биотехнология. Учебное пособие для студентов высших учебных заведений. 2008.

5. Jenkins N., Murphy L., Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008; 39: 113-8.

6. Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology derived Proteins as Drug Substance - Non Clinical and Clinical Issues containing Recombinant Human Erythropoietin, CHMP/94526/05, March 2006.

7. Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance - Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006.

8. Committee for medicinal products for human use (CHMP) Available from: http://www.triskel.com/2%20Guideline%20biotech%20derived%20proteins.pdf (дата обращения 15.01.2015)

9. Guideline on Similar Biological Medicinal Products containing biotechnology-derived proteins as active substance: quality issues (revision 1). EMA., Committee for Medicinal Products for Human Use, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf (дата обращения 14.04.2014).

10. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues, CHMP/BMWP/403543/2010, May 2012.

11. Guideline on similar biological medicinal products containing recombinant interferon alpha, CHMP/BMWP/102046/2006, October 2007.

12. IMS Health 2007 & 2009, Evaluate Pharma, Sandoz analysis. С! ПРЕПАРАТЫ

13. The European Parliament and the Council of the European Union (2004) Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J Eur Union 2004; 47 (L136): 34-57.

14. European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance -Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006. Available from: www.ema.europa.eu/pdfs/human/biosimilar/4283205en Accessed Sept 2, 2010.

15. Sahoo N., Choudhury, K., Manchikanti P. Manufacturing of biodrugs: need for harmonization in regulatory standards. Biodrugs 2009; 23: 217-29.

16. US Food and Drug Administration. Available from: www.fda.org. Accessed Sept 2, 2010.

17. Федерального закона от 24.12.2014 г. «О внесении изменений в Федеральный закон «Об обращении лекарственных средств» и в статью 333.32.1. части второй Налогового кодекса Российской Федерации».

18. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins. EMEA/CHMP/BMWP/14327/2006, December 2007.

19. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues EMEA/CHMP/BMWP/32775/2005_Rev., December 2012.

20. Об обращении лекарственных средств [Электронный ресурс]: Федеральный закон от 12.04.2010 N 61-ФЗ (ред. от 12.03.2014). Доступ из справ.-правовой системы «Консультант Плюс».

21. Guideline on Similar Biological Medicinal Products, CPMP/437/04, October 2005.

22. Солдатов А.А., Авдеева Ж.И., Алпатова Н.А., Медуницын Н.В., Киселевский М.В., Лысикова С.Л. и др. Проблемы регистрации биологических неоригинальных лекарственных препаратов. Биопрепараты 2014; (4); 25-36.